Blockchain Registration Transaction Record

Ventripoint's VMS+ 4.0 Submitted for Approval in China via Green Channel

Ventripoint Diagnostics submits VMS+ 4.0 for NMPA approval in China via green channel. AI-driven cardiac imaging aims to improve diagnosis of heart disease in 330M patients.

This news matters because it signals a major step toward bringing advanced, AI-powered cardiac imaging to China, the world's largest healthcare market. If approved, VMS+™ 4.0 could improve diagnostic accuracy for millions of cardiovascular patients, especially in regions with limited access to MRI. The expedited green channel review means faster deployment, potentially saving lives and reducing healthcare costs. For investors, it represents a validation of Ventripoint's technology and its global expansion strategy.